ELMSFORD, N.Y., Oct. 21, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2015 third quarter results on Wednesday, November 4, 2015, before the U.S. financial markets open.

Richard Smith, President and Chief Executive Officer, and Jeffrey Kreger, Chief Financial Officer, will conduct a conference call as follows:

Date

Wednesday, November 4, 2015

Time

8:30 a.m. EST

Toll free (U.S.)

888-372-9592

International

918-559-5628

Webcast (live and replay)

www.bioscrip.com



A replay of the conference call will be available for two weeks after the call's completion by dialing 855-859-2056 (US) or 404-537-3406 (International) and entering conference call ID number 64965564. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the BioScrip website at www.bioscrip.com.  

About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioscrip-to-host-2015-third-quarter-results-call-300164099.html

SOURCE BioScrip, Inc.

Copyright 2015 PR Newswire

BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioPlus Acquisition Charts.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioPlus Acquisition Charts.